A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Parallel-Group Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)
Phase of Trial: Phase III
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Lemborexant (Primary) ; Zolpidem
- Indications Insomnia
- Focus Therapeutic Use
- Acronyms SUNRISE 1
- Sponsors Eisai Inc
- 07 Mar 2018 According to Eisai Co Ltd media release, company plan to present full results of this study at an upcoming medical meeting in 2018.
- 12 Feb 2018 Status changed from recruiting to completed.
- 09 Aug 2017 Planned End Date changed from 1 Aug 2017 to 1 Nov 2017.